Výsledky vyhledávání - "Camryn Froerer"

Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma

Autor: David D. Stenehjem, Erin B. Bailey, Andrew W. Hahn, Camryn Froerer, Nityam Rathi, Neeraj Agarwal, Sidney VanAlstine

Publikováno v: Clinical genitourinary cancer. 16(5)

Background Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) are a mainstay of treatment for metastatic renal-cell carcinoma. Stool microbiome composition is predictive of response to immunotherapy and cytotoxic chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ded5f2329d27490da6b51b1f3fc9db0
https://pubmed.ncbi.nlm.nih.gov/29858123

Zobrazit plný text záznamu

Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC)

Autor: Neeraj Agarwal, David Gill, Darshan P. Patel, Austin Poole, Benjamin L. Maughan, Lisa A. Cannon-Albright, Andrew W. Hahn, James M. Farnham, Camryn Froerer, Peter Hale, Roberto Nussensveig

Publikováno v: Journal of Clinical Oncology. 36:311-311

311 Background: Currently, there are no predictive biomarkers of response to AA in mCRPC routinely used in the clinic. SLCO2B1 encodes a sodium-independent organic anion transporter that mediates transport of endogenous sex hormones and drugs, includ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e24170a086985c208f6a8b3da5177750
https://doi.org/10.1200/jco.2018.36.6_suppl.311

Zobrazit plný text záznamu

Targeting bacteroides in the stool microbiome and response to treatment (Rx) with first-line VEGFTKI in metastatic renal cell carcinoma (mRCC)

Autor: Neeraj Agarwal, Andrew W. Hahn, David D. Stenehjem, Sidney VanAlstine, Erin B. Bailey, Jeffrey A. Gilreath, Camryn Froerer

Publikováno v: Journal of Clinical Oncology. 36:584-584

584 Background: Diarrhea occurs in ~50% patients with mRCC receiving VEGFTKIs, and is a common cause of VEGFTKI Rx dose reductions/delays/interruptions. Stool bacteroides level directly correlates with diarrhea in these patients on Rx with VEGFTKI (P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9cfcc37258367230047dd9478883f66
https://doi.org/10.1200/jco.2018.36.6_suppl.584

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání